Subsequently, Zhou's group [167] further designed the more effective BCL‐XL PROTAC (XZ739), which could strongly induce BCL‐XL degradation (DC50 = 2.5 nM) and significantly inhibit various cancer cell proliferation. Here, BCL2L1 is linked to cancer.